SLC22A16

Across TCGA pan-cancer cohorts, SLC22A16 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated SLC22A16 data layer compared with 9 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC22A16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A16 expression acts as an unfavorable survival marker, although some lineages such as UCS and LAML show a favorable association.

STAD, COAD, and UCEC are the cancer types where SLC22A16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.332	0.676	<.001	69	view →
COAD	DFS	Quartile	IV	0.335	0.849	<.001	45	view →
UCEC	DFS	Quartile	All	0.496	0.754	.004	36	view →
KICH	DFS	Tertile	All	0.599	0.951	.011	34	view →
UCS	OS	Quartile	II,III,IV	0.888	0.278	<.001	34	view →
LAML	DFS	Tertile	All	0.675	0.408	.003	34	view →
GBM	OS	Quartile	All	0.303	0.518	<.001	33	view →
PAAD	DFS	Tertile	All	0.414	0.233	.009	30	view →
KIRC	DFS	Quartile	III,IV	0.290	0.715	.007	22	view →
CESC	OS	Median	All	0.911	0.835	.006	20	view →
BRCA	OS	Tertile	II,III,IV	0.944	0.972	.026	19	view →
HNSC	OS	Quartile	IV	0.382	0.671	.011	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

SLC22A16–STAD (OS)

Open the STAD breakdown →